Zimbabwe has declined a significant American health deal valued at $367m (£272m) spanning five years because of the United States' request for confidential data.
The decision became public following a official document from December was disclosed, which showed President Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official spokesman has since stated that the US was seeking genetic material for scientific study and commercial purposes but was unwilling to guarantee the benefits from any future medical innovations.
"We will now turn to the difficult and regrettable task of ending our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had provided more than $1.9bn in health funding to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has urged continued dialogue to reach a agreement acceptable to both sides so the nation's critical HIV programme can be sustained.
Broader Background
Zimbabwe's decision comes after a comparable situation in neighbouring Kenya, where a court suspended a related deal with the US after legal challenges were raised about the safety of Kenyans' medical information.
After returning to office recently, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump stated its spending was "inefficient" and his government was seeking government-to-government deals to boost openness and responsibility.
According to statements, 16 nations in Africa have to date agreed to similar health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this partnership would have delivered significant advantages for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy via American-funded initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no corresponding guarantee of access to any scientific breakthroughs – like new medicines or tests – that could result from that provided information," Mangwana explained.
"Effectively, our nation would supply the raw materials for scientific discovery with no certainty that the resulting innovations would be available to our population should a new health crisis arise."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting frameworks previously established via the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system designed to manage future pandemics.
"This framework is designed to ensure that when a nation provides its information, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as hostility towards the US," he added.
"We welcome continued dialogue with our US partners on how future collaboration might be structured in a manner that honours the sovereignty and interests of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the government's concerns, but suggested that negotiations need to persist given that a large portion of the country's HIV programmes relied on external financing.
"If technical issues arise, such as those relating to information security or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," it said.
This impasse emphasises the continuing challenges between accepting crucial international aid and protecting a country's data in an increasingly interconnected world.